Cambrex Corporation

Last updated
Cambrex Corporation
Company typePrivate
Industry Pharmaceuticals
FoundedNew Jersey (1981)
Headquarters East Rutherford, NJ
Key people
Thomas Loewald, CEO
Number of employees
2,200+
Website cambrex.com

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

Contents

Cambrex has cGMP manufacturing facilities in the US (Agawam, MA; Charles City, IA; Durham, NC; High Point, NC; Longmont, CO; Whippany, NJ), Canada (Mirabel, Québec) and Europe (Edinburgh, UK; Karlskoga, Sweden, Milan, Italy, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.

2021 marks 40 years of Cambrex.

History

Cambrex was founded in 1979, when the Ennis Family acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. In 1990, Cambrex was listed on the NYSE.

Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco.

Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. Cambrex acquired two contract biopharmaceutical manufacturing facilities in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. [1]

In 2008, Prosyntest (now Cambrex Tallinn) was acquired, [2] and Steve Klosk was appointed CEO, while remaining President. [3]

To broaden their biocatalysis platform, Cambrex acquired IEP in 2010, now known as Cambrex IEP. [4]

In 2013, Cambrex completed a major 7,000 sq. ft. facility expansion at Charles City, IA to increase API manufacturing capabilities for both existing products and a new product. Investment continued at Charles City, IA with a 45,000 sq. ft temperature and humidity-controlled cGMP warehouse space in 2015. [5]

Cambrex continued to invest in its sites in 2016. Charles City, IA saw a significant expansion of its cGMP API manufacturing and storage capabilities, [6] while large-scale manufacturing capabilities in Karlskoga, Sweden increased with the installation of new multi-purpose reactors and control room upgrades. [7] Additional investment in 2016 saw Cambrex open a new pilot plant at its site in Paullo (Milan) Italy, allowing greater speed and flexibility for small scale API production. [8] In 2016, Cambrex also expanded in its clinical stage API capabilities with the acquisition of PharmaCore, Inc. in High Point, NC, a leading early phase chemistry specialist with expertise in developing, scaling up and manufacturing small molecule APIs for clinical phase projects. [9]

In 2017, Cambrex invested in new small scale capacity at its Charles City, IA facility with the installation of two 500 gallon glass lined reactors and created a third small scale work center, further increasing flexibility for customer projects. [10] Additional investment in Charles City, IA was seen in the form of a new $24 million facility to manufacture highly potent APIs (HPAPIs). [11] Cambrex also expanded its newly acquired High Point, NC facility with the addition of a new $3.2 million, 11,000 sq.ft. analytical laboratory, in response to growing customer demand for analytical development and validation services in support of cGMP products at the clinical stage. [12] Investment in 2017 at the Karlskoga, Sweden facility saw new capacity and continuous flow technology for the production of high purity intermediates. [13]

In 2018, Cambrex acquired Halo Pharma for $425 million adding drug product development and manufacturing capabilities to existing API services. [14] In addition, Cambrex invested $5 million to expand its laboratory facilities in Karlskoga, Sweden which would help increase capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization. [15] Cambrex continued to invest in continuous flow technology at its High Point, NC facility. [16]

In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO. [17] In late 2019, Cambrex was acquired by an affiliate of the Permira funds. [18]

In 2020, Cambrex completed a major expansion at its Edinburgh, UK facility known for solid form screening [19] alongside a biopharmaceutical expansion at its Durham, NC facility. [20] Thomas Loewald was also appointed CEO of Cambrex in September 2020. [21]

In November 2022, it was announced Cambrex had acquired the Waltham-headquartered chemical process development services provider, Snapdragon Chemistry. [22]

Related Research Articles

FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies. FUJIFILM Diosynth Biotechnologies is the world's second largest contract manufacturer of biopharmaceuticals, with manufacturing facilities in Morrisville, North Carolina and College Station, Texas in the United States, Teesside, United Kingdom and Hillerød, Denmark in Europe, and recently added sites in Thousand Oaks, California and Watertown, Massachusetts. FUJIFILM Diosynth Biotechnologies operates a highly automated multipurpose manufacturing facility in College Station, Texas under the federal government's Center for Innovation in Advanced Development and Manufacturing (CIADM) program, which is the largest scale-out cell culture manufacturing facility in the United States.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Charles River Laboratories</span> American biotechnology and pharmaceutical corporation

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

<span class="mw-page-title-main">Patheon</span>

Patheon is a service brand within Thermo Fisher Scientific’s brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

<span class="mw-page-title-main">JN-International Medical Corporation</span> Pharmaceutical company in Nebraska, United States

JN-International Medical Corporation (JNIMC) is a U.S.-based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska.

<span class="mw-page-title-main">Therapure BioPharma Inc</span>

Therapure BioPharma, Inc. is a Canadian biopharmaceutical industry and biotechnology company, headquartered in Mississauga, Ontario, a privately held, integrated Contract Development and Manufacturing Organization (CDMO). Founded in 2008, the firm provides a range of therapeutic protein development and manufacturing services including; technology transfer & process development, analytical development and testing, scale up and cGMP manufacturing, and aseptic fill/finish and lyophilization. As of 2010, the company has over 90 employees. In 2020, Therapure was acquired by Resilience.

SynCo Bio Partners B.V. is a biopharmaceutical good manufacturing practices (GMP) contract manufacturing organization (CMO) located in Amsterdam, the Netherlands, licensed for clinical and commercial GMP manufacturing of bulk drug substances and drug products. SynCo offers a fully integrated range of biopharmaceutical development and manufacturing services supporting small biotech to large pharmaceutical organizations worldwide from the earliest stages in process development, through preclinical and clinical trials, approval and market supply.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. It's market presence is more than 100+ countries.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

Curia is a contract research and manufacturing organization that provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries. Founded in 1991, Curia operates in the United States, Europe and Asia, with its headquarters located in Albany, New York. Curia has announced deals and collaborations with such companies as Pfizer Inc., Merck & Co., Eli Lilly and Company, Takeda, Genentech, Bristol-Myers Squibb Co. and GE.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.

Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida. The company was founded with research in nanometer-scale particle technology to develop new drug delivery technologies and increase the efficacy of existing drugs. In 2016, the company changed their strategic focus and became a biologics contract development and manufacturing company (CDMO) specializing in the manufacturing of vaccines, monoclonal antibodies, recombinant proteins, virus and nucleic acids.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

<span class="mw-page-title-main">WuXi Biologics</span> Chinese pharmaceutical company

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

<span class="mw-page-title-main">Laurus Labs</span> Indian pharmaceutical company

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava.

Wilhelm Róbert Wessman is an Icelandic business executive and founder of the pharmaceutical and biotechnology companies Alvotech and Alvogen.

Rentschler Biopharma SE is an contract development and manufacturing organization (CDMO). It is part of Dr. Rentschler Holding GmbH & Co. KG and its employees make up the majority of the 1300 workers employed by the parent organization.

References

  1. ↑ "CDMO | News | Sale of Bio Business Completed". Cambrex. 2007-02-06. Retrieved 2021-10-04.
  2. ↑ "CDMO | News | Cambrex Signs Agreement to Acquire Prosyntest AS". Cambrex. 2008-01-07. Retrieved 2021-10-04.
  3. ↑ "CDMO | News | Steven Klosk Appointed as President and CEO". Cambrex. 2008-05-15. Retrieved 2021-10-04.
  4. ↑ "CDMO | News | Cambrex Acquires IEP GmbH". Cambrex. 2010-03-22. Retrieved 2021-10-04.
  5. ↑ "CDMO | News | Expansion of Large Scale API Capacity". Cambrex. 2015-02-06. Retrieved 2021-10-04.
  6. ↑ "CDMO| News | Investment in Large Scale API Manufacture in Charles City". Cambrex. 2016-07-12. Retrieved 2021-10-04.
  7. ↑ "CDMO | News | Investment and Expansion at Karlskoga Facility". Cambrex. 2016-09-06. Retrieved 2021-10-04.
  8. ↑ "CDMO | News | New Pilot Plant in Milan". Cambrex. 2016-10-03. Retrieved 2021-10-04.
  9. ↑ "CDMO | News | Acquisition of PharmaCore, Inc". Cambrex. 2016-10-07. Retrieved 2021-10-04.
  10. ↑ "CDMO | News | New Small Scale Capacity at Charles City, IA". Cambrex. 2017-11-08. Retrieved 2021-10-04.
  11. ↑ "CDMO | News | New HPAPI Manufacturing Capacity in Charles City, IA". Cambrex. 2017-08-08. Retrieved 2021-10-04.
  12. ↑ "CDMO | News | New Analytical Development & Method Validation Lab". Cambrex. 2017-08-30. Retrieved 2021-10-04.
  13. ↑ "CDMO | News | New Capacity & Continuous Flow Technology in Karlskoga". Cambrex. 2017-05-30. Retrieved 2021-10-04.
  14. ↑ Corporation, Cambrex (2018-09-12). "Cambrex Completes Acquisition of Halo Pharma". GlobeNewswire News Room (Press release). Retrieved 2020-05-18.
  15. ↑ "CDMO | News | New Laboratory Expansion in Karlskoga". Cambrex. 2018-05-31. Retrieved 2021-10-04.
  16. ↑ "CDMO | News | New Continuous Flow Technology at High Point, NC". Cambrex. 2018-04-17. Retrieved 2021-10-04.
  17. ↑ outsourcing-pharma.com (21 November 2018). "Cambrex acquires Avista for $252m, becomes integrated CDMO". outsourcing-pharma.com. Retrieved 2020-05-18.
  18. ↑ "CDMO | News | Completed Acquisition by The Permira Funds". Cambrex. 2019-12-04. Retrieved 2021-09-29.
  19. ↑ "CDMO | News | Expansion Completed at Edinburgh Facility". Cambrex. 2020-10-12. Retrieved 2021-10-04.
  20. ↑ "CDMO | News | Biopharmaceutical Expansion at Durham, NC". Cambrex. 2020-04-07. Retrieved 2021-10-04.
  21. ↑ "CDMO | News | Announcement of Thomas Loewald as CEO". Cambrex. 2020-06-18. Retrieved 2021-10-04.
  22. ↑ "Cambrex set to acquire Snapdragon Chemistry". www.manufacturingchemist.com. Retrieved 2022-11-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.